There are currently 6 active clinical trials seeking participants for SARS-CoV Infection research studies. The states with the highest number of trials for SARS-CoV Infection participants are Florida, California, Texas and Minnesota.
Mitoquinone/mitoquinol Mesylate As Oral and Safe Postexposure Prophylaxis for Covid-19
NCT05886816
Recruiting
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/10/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: SARS-CoV Infection, COVID-19
Register for Updates
Imaging Immune Activation in COVID-19
NCT04815096
Recruiting
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Covid19, SARS-CoV Infection
Register for Updates
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
NCT04802408
Recruiting
Adults (aged 18-65 years) recently diagnosed with SARS-CoV-2 infection who use a 4-day combined intervention of nasal washes with 1% baby shampoo solution and oral gargles with Listerine Antiseptic® will have a reduced SARS-CoV-2 viral load compared to those using nasal and oral washes with normal saline. This combined intervention should be acceptable, tolerable and safe in this population. To test this, investigators are conducting a trial comparing the efficacy of a number of washes in reduci... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/25/2024
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania +1 locations
Conditions: Covid19, SARS-CoV Infection
Register for Updates
KIDney Injury in Times of COVID-19 (KIDCOV)
NCT04705766
Recruiting
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine sam... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: UCSF, San Francisco, California +2 locations
Conditions: SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
All
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida +16 locations
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates
COVID-19 Vaccine Response in Chronic Respiratory Conditions
NCT05313087
Recruiting
The investigators will assess the antibody, T cell and B cell responses to SARS-CoV-2 vaccination before and every 3 months for 18 months after the initial vaccination or subsequent vaccinations (boosters) in adults and children including patients with chronic medical conditions.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: National Jewish Health, Denver, Colorado
Conditions: SARS-CoV Infection
Register for Updates